MX394840B - Nuevos metodos para el tratamiento de la esclerosis multiple. - Google Patents
Nuevos metodos para el tratamiento de la esclerosis multiple.Info
- Publication number
- MX394840B MX394840B MX2019011547A MX2019011547A MX394840B MX 394840 B MX394840 B MX 394840B MX 2019011547 A MX2019011547 A MX 2019011547A MX 2019011547 A MX2019011547 A MX 2019011547A MX 394840 B MX394840 B MX 394840B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- multiple sclerosis
- new methods
- methods
- hydroxycyclohexylamino
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- ADZBMFGQQWPHMJ-RHSMWYFYSA-N 4-[[2-[[(1r,2r)-2-hydroxycyclohexyl]amino]-1,3-benzothiazol-6-yl]oxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C3SC(N[C@H]4[C@@H](CCCC4)O)=NC3=CC=2)=C1 ADZBMFGQQWPHMJ-RHSMWYFYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a métodos de tratamiento de esclerosis múltiple, esclerosis lateral amiotrófica (ALS) o enfermedad de Alzheimer en un sujeto que lo necesita, mediante la administración de una cantidad eficaz de 4-(2-((1R,2R)-2-hidroxiciclohexilamino)benzotiazol-6-iloxi)-N-metilpicolinamida o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762477717P | 2017-03-28 | 2017-03-28 | |
| PCT/IB2018/052057 WO2018178852A1 (en) | 2017-03-28 | 2018-03-26 | New methods for the treatment of multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019011547A MX2019011547A (es) | 2019-11-28 |
| MX394840B true MX394840B (es) | 2025-03-24 |
Family
ID=62002180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019011547A MX394840B (es) | 2017-03-28 | 2018-03-26 | Nuevos metodos para el tratamiento de la esclerosis multiple. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200093801A1 (es) |
| EP (2) | EP3600311B1 (es) |
| JP (2) | JP2020515555A (es) |
| KR (1) | KR20190128703A (es) |
| CN (2) | CN116139135A (es) |
| AU (1) | AU2018242535B2 (es) |
| BR (1) | BR112019020093A2 (es) |
| CA (1) | CA3057040A1 (es) |
| CL (1) | CL2019002704A1 (es) |
| IL (1) | IL269681A (es) |
| MX (1) | MX394840B (es) |
| RU (2) | RU2022102195A (es) |
| WO (1) | WO2018178852A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022013031A (es) * | 2020-04-21 | 2023-01-04 | Novartis Ag | Regimen de dosificacion para el tratamiento de una enfermedad modulada por csf-1r. |
| WO2026164197A1 (en) * | 2025-01-30 | 2026-08-06 | Otsuka Pharmaceutical Co., Ltd. | Thiadiazole compound as csf1r inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101464385B1 (ko) | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법 |
| US20100261679A1 (en) * | 2007-10-18 | 2010-10-14 | James Sutton | CSF-1R, Inhibitors, Compositions, and Methods of Use |
| WO2012151541A1 (en) * | 2011-05-05 | 2012-11-08 | Novartis Ag | Csf-1r inhibitors for treatment of brain tumors |
| US20150119267A1 (en) * | 2012-04-16 | 2015-04-30 | Sloan-Kettering Institute For Cancer Research | Inhibition of colony stimulating factor-1 receptor signaling for the treatment of brain cancer |
| WO2015181815A1 (en) * | 2014-05-25 | 2015-12-03 | Medwell Laboratories Ltd. | Methods for treating multiple sclerosis |
| JP6851322B2 (ja) * | 2015-05-27 | 2021-03-31 | ユーシービー バイオファルマ エスアールエル | 神経疾患を治療する方法 |
| CN114230571B (zh) * | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| EA038531B1 (ru) * | 2016-03-25 | 2021-09-10 | Аб Сьянс | Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб |
-
2018
- 2018-03-26 CA CA3057040A patent/CA3057040A1/en active Pending
- 2018-03-26 BR BR112019020093A patent/BR112019020093A2/pt not_active Application Discontinuation
- 2018-03-26 EP EP18718215.9A patent/EP3600311B1/en active Active
- 2018-03-26 AU AU2018242535A patent/AU2018242535B2/en not_active Ceased
- 2018-03-26 RU RU2022102195A patent/RU2022102195A/ru unknown
- 2018-03-26 WO PCT/IB2018/052057 patent/WO2018178852A1/en not_active Ceased
- 2018-03-26 JP JP2019552879A patent/JP2020515555A/ja active Pending
- 2018-03-26 EP EP23212604.5A patent/EP4324523A3/en not_active Withdrawn
- 2018-03-26 RU RU2019134182A patent/RU2765820C2/ru active
- 2018-03-26 CN CN202310210167.XA patent/CN116139135A/zh active Pending
- 2018-03-26 KR KR1020197031086A patent/KR20190128703A/ko not_active Ceased
- 2018-03-26 MX MX2019011547A patent/MX394840B/es unknown
- 2018-03-26 US US16/495,754 patent/US20200093801A1/en not_active Abandoned
- 2018-03-26 CN CN201880021740.XA patent/CN110475555A/zh active Pending
-
2019
- 2019-09-24 CL CL2019002704A patent/CL2019002704A1/es unknown
- 2019-09-26 IL IL26968119A patent/IL269681A/en unknown
-
2023
- 2023-07-31 JP JP2023124884A patent/JP2023159125A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019011547A (es) | 2019-11-28 |
| CL2019002704A1 (es) | 2020-01-10 |
| AU2018242535B2 (en) | 2021-01-28 |
| KR20190128703A (ko) | 2019-11-18 |
| EP3600311A1 (en) | 2020-02-05 |
| CA3057040A1 (en) | 2018-10-04 |
| CN110475555A (zh) | 2019-11-19 |
| RU2765820C2 (ru) | 2022-02-03 |
| AU2018242535A1 (en) | 2019-10-03 |
| EP4324523A3 (en) | 2024-05-01 |
| JP2023159125A (ja) | 2023-10-31 |
| IL269681A (en) | 2019-11-28 |
| CN116139135A (zh) | 2023-05-23 |
| RU2022102195A (ru) | 2022-03-05 |
| EP4324523A2 (en) | 2024-02-21 |
| JP2020515555A (ja) | 2020-05-28 |
| EP3600311B1 (en) | 2024-05-15 |
| US20200093801A1 (en) | 2020-03-26 |
| RU2019134182A (ru) | 2021-04-28 |
| WO2018178852A1 (en) | 2018-10-04 |
| RU2019134182A3 (es) | 2021-07-20 |
| BR112019020093A2 (pt) | 2020-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| PH12017500493A1 (en) | Combination therapy | |
| MX383499B (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| AR111693A1 (es) | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga | |
| MX387115B (es) | Métodos para tratar la influenza. | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| JOP20200230B1 (ar) | ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها | |
| BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
| PH12015501858B1 (en) | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | |
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| MX380531B (es) | Agonistas del receptor activado por proliferador de peroxisoma (ppar), compuestos, composiciones farmacéuticas y métodos para usar los mismos. | |
| MX2017006692A (es) | Trastornos neurodegenerativos. | |
| EA201892536A1 (ru) | Фармацевтические носители, содержащие микрорнк, для применения в лечении фиброзных заболеваний, вызванных гипергликемией | |
| MX380290B (es) | Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos. | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| MX2016008968A (es) | Compuestos organicos. | |
| MX375924B (es) | Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo. | |
| CO2017004785A2 (es) | N-[4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il]-2-metilpiridin-5-carboxamida o una sal farmacéutica como antagonista del receptor a2a | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| EP4324523A3 (en) | New methods for the treatment of multiple sclerosis | |
| EA201792109A1 (ru) | Конденсированные с тетрагидрофураном производные аминогидротиазина, пригодные для лечения болезни альцгеймера | |
| EA201891688A1 (ru) | Адамантановое производное и его применение | |
| CL2015003679A1 (es) | Agentes terapéuticos para el uso en la profilaxis y/o el tratamiento de trastornos del movimiento hiperquineticoico |